Pediatric Nephrology

, 24:91 | Cite as

Treatment of severe Henoch–Schönlein and immunoglobulin A nephritis. A single center experience

  • Stella Edström Halling
  • Magnus P. Söderberg
  • Ulla B. Berg
Original Article

Abstract

Our aim was to report the effect of two treatment regimens in 43 cases of severe Henoch–Schönlein nephritis (HSN) and immunoglobulin A nephritis (IgAN) (24 HSN, 19 IgAN). Group A, 11 HSN and 7 IgAN, 88% with an International Study of Kidney Disease in Children (ISKDC) biopsy grade ≥ III and severe clinical features, were treated with corticosteroids, cyclophosphamide (CYC-P) and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB). Group B, 12 HSN and 13 IgAN, 72% with biopsy findings as above and 52% with severe clinical features, were treated with ACEi/ARB ± corticosteroids. The outcome classification was: (a) healthy; (b) mild proteinuria, normal glomerular filtration rate (GFR); (c) active renal disease; (d) chronic renal failure. Twenty-six patients had a good outcome (a + b). The 17 children with poor outcome (c + d) had lower GFR at onset and at follow-up, higher albumin excretion at follow-up, and higher percentage of segmental glomerulosclerosis in the renal biopsy, than those with good outcome. Treatment with corticosteroids, CYC-P and ACEi/ARB was effective in increasing GFR, reducing proteinuria and decreasing the disease activity index. The proteinuria had decreased at follow-up in both groups. In group A, GFR increased and histopathological activity index declined after treatment. The outcome did not differ between groups A and B. The effects of treatment did not differ between HSN and IgAN.

Keywords

Methylprednisolone Cyclophosphamide Renal biopsy findings Proteinuria Glomerular filtration rate Segmental glomerulosclerosis IgA nephritis Henoch–Schönlein nephritis 

Notes

Acknowledgments

This study was financially supported by the Samariten Foundation, the Frimurarna Association, the Jerring Foundation and the Swedish Medical Research Council (no. 6864). Financial support was also provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and the Karolinska Institutet.

References

  1. 1.
    D’Amico G (2004) Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24:179–196PubMedCrossRefGoogle Scholar
  2. 2.
    Coppo R, Mazzucco G, Caglioni L, Lupo A (1997) Long-term prognosis of Henoch-Schonlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schonlein purpura. Nephrol Dial Transplant 12:2277–2283PubMedCrossRefGoogle Scholar
  3. 3.
    Coppo R, Andrulli S, Amore A, Gianoglio B, Conti G, Peruzzi L, Locatelli F, Cagnoli L (2006) Predictors of outcome in Henoch-Schonlein nephritis in children and adults. Am J Kidney Dis 47:993–1003PubMedCrossRefGoogle Scholar
  4. 4.
    Haas M (1997) Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 29:829–842PubMedCrossRefGoogle Scholar
  5. 5.
    Wyatt RJ, Emancipator SN, Kon V, Waldo FB, Donadio J, Grande JP, Andreoli SP, Glassock RJ (1997) IgA nephropathy databank: development of a system for management of renal biopsy acquired data. Am J Kidney Dis 26:817–828CrossRefGoogle Scholar
  6. 6.
    Andreoli SP, Bergstein JM (1989) Treatment of severe IgA nephropathy in children. Pediatr Nephrol 3:248–253PubMedCrossRefGoogle Scholar
  7. 7.
    Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA (2002) Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61:1098–1114PubMedCrossRefGoogle Scholar
  8. 8.
    Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB (2001) Treatment of Henoch-Schonlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol 21:128–133PubMedCrossRefGoogle Scholar
  9. 9.
    Iijima K, Ito-Kariya S, Nakamura H, Yoshikawa N (1998) Multiple combined therapy for severe Henoch-Schonlein nephritis in children. Pediatr Nephrol 12:244–248PubMedCrossRefGoogle Scholar
  10. 10.
    Oner A, Tinaztepe K, Erdogan O (1995) The effect of triple therapy on rapidly progressive type of Henoch-Schonlein nephritis. Pediatr Nephrol 9:6–10PubMedCrossRefGoogle Scholar
  11. 11.
    Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243PubMedCrossRefGoogle Scholar
  12. 12.
    Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157–163PubMedCrossRefGoogle Scholar
  13. 13.
    Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353:883–887PubMedCrossRefGoogle Scholar
  14. 14.
    Ronkainen J, Autio-Harmainen H, Nuutinen M (2003) Cyclosporin A for the treatment of severe Henoch-Schonlein glomerulonephritis. Pediatr Nephrol 18:1138–1142PubMedCrossRefGoogle Scholar
  15. 15.
    Scharer K, Krmar R, Querfeld U, Ruder H, Waldherr R, Schaefer F (1999) Clinical outcome of Schonlein-Henoch purpura nephritis in children. Pediatr Nephrol 13:816–823PubMedCrossRefGoogle Scholar
  16. 16.
    Shenoy M, Bradbury MG, Lewis MA, Webb NJ (2007) Outcome of Henoch-Schonlein purpura nephritis treated with long-term immunosuppression. Pediatr Nephrol 22:1717–1722PubMedCrossRefGoogle Scholar
  17. 17.
    Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Kim PK, Jeong HJ (2005) Can azathioprine and steroids alter the progression of severe Henoch-Schonlein nephritis in children? Pediatr Nephrol 20:1087–1092PubMedCrossRefGoogle Scholar
  18. 18.
    Tanaka H, Suzuki K, Nakahata T, Ito E, Waga S (2003) Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatr Nephrol 18:347–350PubMedGoogle Scholar
  19. 19.
    Wyatt RJ, Hogg RJ (2001) Evidence-based assessment of treatment options for children with IgA nephropathies. Pediatr Nephrol 16:156–167PubMedCrossRefGoogle Scholar
  20. 20.
    Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H (2006) Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 1:511–517PubMedCrossRefGoogle Scholar
  21. 21.
    Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M (1999) A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 10:101–109Google Scholar
  22. 22.
    Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linne T (2007) IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:1880–1888PubMedCrossRefGoogle Scholar
  23. 23.
    Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K, Ito E, Waga S (2004) Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int 46:576–579PubMedCrossRefGoogle Scholar
  24. 24.
    Meadow SR, Glasgow EF, White RH, Moncrieff MW, Cameron JS, Ogg CS (1972) Schonlein-Henoch nephritis. Q J Med 41:241–58PubMedGoogle Scholar
  25. 25.
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576CrossRefGoogle Scholar
  26. 26.
    Berg U, Bohlin AB (1982) Renal hemodynamics in minimal change nephrotic syndrome in childhood. Int J Pediatr Nephrol 3:187–192PubMedGoogle Scholar
  27. 27.
    Counahan R, Winterborn MH, White RH, Heaton JM, Meadow SR, Bluett NH, Swetschin H, Cameron JS, Chantler C (1977) Prognosis of Henoch-Schonlein nephritis in children. BMJ 2:11–14PubMedCrossRefGoogle Scholar
  28. 28.
    Foster BJ, Bernard C, Drummond KN, Sharma AK (2000) Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr 136:370–375PubMedCrossRefGoogle Scholar
  29. 29.
    D’Amico G (2000) Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 36:227–237PubMedCrossRefGoogle Scholar
  30. 30.
    Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D (2002) Henoch-Schonlein purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 13:1271–1278PubMedCrossRefGoogle Scholar
  31. 31.
    Ronkainen J, Ala-Houhala M, Huttunen NP, Jahnukainen T, Koskimies O, Ormala T, Nuutinen M (2003) Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria. Clin Nephrol 60:80–84PubMedGoogle Scholar
  32. 32.
    Tarshish P, Bernstein J, Edelmann CM Jr (2004) Henoch-Schonlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 19:51–56PubMedCrossRefGoogle Scholar
  33. 33.
    Goldstein AR, Bernstein J, Edelmann CM Jr (1992) Long-term follow-up of childhood Henoch-Schonlein nephritis. Lancet 339:280–282PubMedCrossRefGoogle Scholar
  34. 34.
    Davin JC, Weening JJ (2001) Henoch-Schonlein purpura nephritis: an update. Eur J Pediatr 160:689–695PubMedGoogle Scholar
  35. 35.
    Coppo R, D’Amico G (2005) Factors predicting progression of IgA nephropathies. J Nephrol 18:503–512PubMedGoogle Scholar
  36. 36.
    Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study. Lancet 360:666–670PubMedCrossRefGoogle Scholar
  37. 37.
    Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino DA (1994) Prognostic indicators in children with IgA nephropathy—report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 8:15–20PubMedCrossRefGoogle Scholar
  38. 38.
    Yoshikawa N, Ito H, Nakamura H (1992) Prognostic indicators in childhood IgA nephropathy. Nephron 60:60–67PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2008

Authors and Affiliations

  • Stella Edström Halling
    • 1
  • Magnus P. Söderberg
    • 2
  • Ulla B. Berg
    • 1
  1. 1.Department of Clinical Science, Intervention and Technology, Division of Pediatrics, Karolinska InstitutetKarolinska University Hospital, HuddingeStockholmSweden
  2. 2.Department of Laboratory Medicine, Division of PathologyKarolinska University Hospital, HuddingeStockholmSweden

Personalised recommendations